Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CCR1-Antagonist · 1 trial · 1 indication
EAPP was assessed by a composite parameter, consisting of the reading of the visual analog scale (VAS) and the intake of rescue medication
| Arm | Type | Description |
|---|---|---|
| CCR-1 Receptor Antagonist | EXPERIMENTAL | Subjects received 600 mg (2 x 300 mg tablets) of CCR-1 Receptor Antagonist 3 times daily |
| Placebo | PLACEBO_COMPARATOR | Subjects received placebo corresponding to verum |
| Name | Type | Description |
|---|---|---|
| CCR1-Antagonist (BAY86-5047, ZK811752) | DRUG | Given orally in a dose of 600 mg three times daily over 12 weeks |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Pain associated with proven endometriosis, as determined by diagnostic measures within 24 months prior to start of treatment * Women with cyclic menstrual bleeding- Good general health * Willingness to use a barrier contraceptive method such as condoms but no hormonal contrace...
CCR1-Antagonist is an investigational small molecule being developed for the treatment of endometriosis. It is designed to address endometriosis-associated pelvic pain as a non-hormonal therapeutic option. The drug is currently in Phase 2 clinical development and has completed one trial evaluating its efficacy in this patient population.
CCR1-Antagonist is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded under the ticker symbol BAYRY on the OTC market. The company is conducting clinical research to evaluate this investigational drug for the treatment of endometriosis.
CCR1-Antagonist is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is still investigational and has not been approved by regulatory authorities. Further clinical development may be required to establish its safety and efficacy.
CCR1-Antagonist has been studied in one completed Phase 2 clinical trial, identified as NCT00185341. This trial was titled 'Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain' and enrolled 110 female participants aged 18 years and older across multiple European countries.
CCR1-Antagonist targets the CCR1 receptor, a chemokine receptor involved in inflammatory processes. By blocking this receptor, the drug aims to reduce inflammation and pain associated with endometriosis. This mechanism offers a non-hormonal approach to managing endometriosis symptoms, potentially providing an alternative to hormonal therapies.
CCR1-Antagonist is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for endometriosis. The completed Phase 2 trial evaluated its efficacy for endometriosis-associated pelvic pain, but the drug has not yet received regulatory approval and remains under clinical investigation.